InflaRx 新闻与活动
在场
InflaRx 是一家在股票代码 IFRX (DE) 下上市的公司。
高管
查看带有其 25 名主要高管的组织结构图
InflaRx 搜索最多的简介
- Niels Riedemann, Chief Executive Officer and Director
- Richard Brudnick, Non-Executive Director
- Nicolas Fulpius, Chairman of the Board
创建提醒
跟踪 InflaRx 的高管变动
生物技术
InflaRx 拥有 2,350 家竞争者，其中包括 Incyte (美国(美洲))、Eurofins (卢森堡) 和 Anthos Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Reunion Neuroscience 刚刚宣布为 103 筹款数百万美元。 (公布2025八月8号).
- Shattuck Labs 刚刚宣布为 103 筹款数百万美元。 (公布2025八月8号).
- Impact Therapeutics 刚刚宣布为 55 筹款数百万美元。 (公布2025八月8号).
生物技术 行业的其他推荐联系人
消息
InflaRx 的最新新闻稿
- 11-2024 InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
- 11-2024 InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
- 11-2024-InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
- 10-2024-InflaRx to Report Third Quarter 2024 Results on November 8 and to Participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 11
- 09-2024-InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
- 09-2024-InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
- 08-2024-InflaRx Announces Participation in September Investor Events
- 07-2024-InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
- 08-2024-InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
- 07-2024-InflaRx to Report Second Quarter 2024 Results on August 8, 2024
- View more press releases Close
